First-in-human study of a leadless pacemaker system for left bundle branch area pacing

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023884%3A_____%2F25%3A00010237" target="_blank" >RIV/00023884:_____/25:00010237 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/25:10511084

Výsledek na webu

<a href="https://pubmed.ncbi.nlm.nih.gov/40300740/" target="_blank" >https://pubmed.ncbi.nlm.nih.gov/40300740/</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.hrthm.2025.04.030" target="_blank" >10.1016/j.hrthm.2025.04.030</a>

Jazyk výsledku

angličtina

Název v původním jazyce

First-in-human study of a leadless pacemaker system for left bundle branch area pacing

Popis výsledku v původním jazyce

BACKGROUND: Leadless pacemakers (LPs) are limited by the current inability to perform left bundle branch area pacing (LBBAP). OBJECTIVE: The purpose of this first-in-human acute feasibility study was to evaluate the safety and performance of a novel helix-based LP with an extended electrode for LBBAP (LPCSP). METHODS: After obtaining informed consent, the LPCSP (Aveir CSP LP) was temporarily deployed in patients with indications for LP implantation. The LPCSP was introduced from the right internal jugular (IJ) vein and temporarily implanted deep into the interventricular septum (IVS) under fluoroscopic and intracardiac echocardiographic guidance. The primary safety endpoint was freedom from serious device adverse events (SADEs) within 1 month of the implant procedure. The primary performance endpoints were intraprocedural electrical parameters, including pacing threshold, impedance, and sensed R-wave amplitude. The LPCSP then was removed, and a conventional LP was implanted in the right ventricle using the same IJ access. RESULTS: Among 14 enrolled patients (age 69.4 ± 9.9 years, 71% male), the LPCSP was successfully implanted into the IVS in 10 patients. Pacing threshold (1.2 ± 0.6 V at 0.4 ms), R-wave amplitude (10.2 ± 4.1 mV), and impedance (373 ± 56 Ω) were acceptable. LBBAP capture was observed in 5 patients, segmented into direct capture of the left bundle branch (n = 1) and left ventricular septal pacing (n = 4). Deep septal pacing was observed in 3 additional patients. Freedom from SADEs within 1 month of the implant procedure was 85.7%. CONCLUSION: This first-in-human study demonstrated acute successful implantation of the LPCSP with clinically acceptable intraprocedural electrical performance and safety.

Název v anglickém jazyce

First-in-human study of a leadless pacemaker system for left bundle branch area pacing

Popis výsledku anglicky

BACKGROUND: Leadless pacemakers (LPs) are limited by the current inability to perform left bundle branch area pacing (LBBAP). OBJECTIVE: The purpose of this first-in-human acute feasibility study was to evaluate the safety and performance of a novel helix-based LP with an extended electrode for LBBAP (LPCSP). METHODS: After obtaining informed consent, the LPCSP (Aveir CSP LP) was temporarily deployed in patients with indications for LP implantation. The LPCSP was introduced from the right internal jugular (IJ) vein and temporarily implanted deep into the interventricular septum (IVS) under fluoroscopic and intracardiac echocardiographic guidance. The primary safety endpoint was freedom from serious device adverse events (SADEs) within 1 month of the implant procedure. The primary performance endpoints were intraprocedural electrical parameters, including pacing threshold, impedance, and sensed R-wave amplitude. The LPCSP then was removed, and a conventional LP was implanted in the right ventricle using the same IJ access. RESULTS: Among 14 enrolled patients (age 69.4 ± 9.9 years, 71% male), the LPCSP was successfully implanted into the IVS in 10 patients. Pacing threshold (1.2 ± 0.6 V at 0.4 ms), R-wave amplitude (10.2 ± 4.1 mV), and impedance (373 ± 56 Ω) were acceptable. LBBAP capture was observed in 5 patients, segmented into direct capture of the left bundle branch (n = 1) and left ventricular septal pacing (n = 4). Deep septal pacing was observed in 3 additional patients. Freedom from SADEs within 1 month of the implant procedure was 85.7%. CONCLUSION: This first-in-human study demonstrated acute successful implantation of the LPCSP with clinically acceptable intraprocedural electrical performance and safety.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Heart Rhythm

ISSN

1547-5271

e-ISSN

—

Svazek periodika

22

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

8

Strana od-do

2010-2017

Kód UT WoS článku

001544833200028

EID výsledku v databázi Scopus

2-s2.0-105007024256